Enhanced Inflammasome Activity in Systemic Lupus Erythematosus Is Mediated via Type I Interferon–Induced Up‐Regulation of Interferon Regulatory Factor 1
- 31 May 2017
- journal article
- systemic lupus-erythematosus
- Published by Wiley in Arthritis & Rheumatology
- Vol. 69 (9) , 1840-1849
Abstract
Objective: The inflammasome complex is a driver of organ damage in patients with systemic lupus erythematosus (SLE). Although type I interferons (IFNs) are well established as mediators of SLE pathogenesis, their role in inflammasome activation in SLE has not been assessed. The aim of this study was to examine type I IFNs as regulators of the inflammasome.Methods: SLE patients fulfilled ≥4 American College of Rheumatology criteria and were recruited from the University of Michigan Lupus Cohort. Primary monocytes were isolated from SLE patients or healthy controls by negative selection, treated with inflammasome activators in the presence or absence of IFNα, and IL‐1β secretion was measured by enzyme‐linked immunosorbent assay. Expression levels of IFN and inflammasome‐related molecules were assessed by real‐time polymerase chain reaction and Western blotting. IFN regulatory factor 1 (IRF‐1) expression was specifically down‐regulated by small interfering RNA (siRNA) transfection and a chemical inhibitor.Results: Monocytes from patients with SLE exhibited increased expression and enhanced activation of the inflammasome by ATP when compared with control monocytes. Expression of inflammasome and IFN‐regulated genes was significantly correlated in monocytes from SLE patients but not in control monocytes. Inflammasome activity was increased after prolonged exposure to IFNα. Reduction of IRF‐1 expression via siRNA blocked caspase 1 up‐regulation after treatment with IFNα. Importantly, hyperactivity of the inflammasome in the monocytes of SLE patients was significantly reduced after knockdown or inhibition of IRF‐1.Conclusion: Prolonged type I IFN exposure, as seen in SLE patients, primes monocytes for robust inflammasome activation in an IRF‐1–dependent manner. IRF‐1 inhibition may serve as a novel target for treatment of SLE‐associated inflammation and organ damage.Keywords
Funding Information
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R03‐AR‐066337, K08‐AR‐063668, R03AR066337)
- Arthritis National Research Foundation
- National Institutes of Health
This publication has 52 references indexed in Scilit:
- Murine BAFF expression is up-regulated by estrogen and interferons: Implications for sex bias in the development of autoimmunityMolecular Immunology, 2013
- U1-Small Nuclear Ribonucleoprotein Activates the NLRP3 Inflammasome in Human MonocytesThe Journal of Immunology, 2012
- Inflammasome Activation of IL-18 Results in Endothelial Progenitor Cell Dysfunction in Systemic Lupus ErythematosusThe Journal of Immunology, 2011
- Interferon‐α accelerates murine systemic lupus erythematosus in a T cell–dependent mannerArthritis & Rheumatism, 2010
- The NLRP3 Inflammasome Promotes Renal Inflammation and Contributes to CKDJournal of the American Society of Nephrology, 2010
- Lupus Serum IgG Induces Skin Inflammation through the TNFR1 Signaling PathwayThe Journal of Immunology, 2010
- Deficiency of Type I IFN Receptor in Lupus-Prone New Zealand Mixed 2328 Mice Decreases Dendritic Cell Numbers and Activation and Protects from DiseaseThe Journal of Immunology, 2009
- P2X7 Receptor-Stimulated Secretion of MHC Class II-Containing Exosomes Requires the ASC/NLRP3 Inflammasome but Is Independent of Caspase-1The Journal of Immunology, 2009
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Derivation of the sledai. A disease activity index for lupus patientsArthritis & Rheumatism, 1992